Literature DB >> 18977348

The role of steroids in outflow resistance.

Abbot F Clark1, Robert J Wordinger.   

Abstract

Glucocorticoid (GC)-induced ocular hypertension and secondary iatrogenic open-angle glaucoma are serious side effects of GC therapy. Its clinical presentation is similar in many ways to primary open-angle glaucoma, including increased aqueous outflow resistance and morphological and biochemical changes to the trabecular meshwork (TM). Therefore, a large number of studies have examined the effects of GCs on TM cells and tissues. GCs have diverse effects on the TM, altering TM cell functions, gene expression, extracellular matrix metabolism, and cytoskeletal structure. Some or all of these effects may be responsible for the increased outflow resistance associated with GC therapy. In contrast to GCs, several different classes of steroids appear to lower IOP. Additional research will help better define the molecular mechanisms responsible for GC-induced ocular hypertension and steroid-induced IOP lowering activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18977348     DOI: 10.1016/j.exer.2008.10.004

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  106 in total

1.  Dexamethasone-associated cross-linked actin network formation in human trabecular meshwork cells involves β3 integrin signaling.

Authors:  Mark S Filla; Marie K Schwinn; Amanda K Nosie; Ross W Clark; Donna M Peters
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-05       Impact factor: 4.799

2.  Hic-5 Regulates Actin Cytoskeletal Reorganization and Expression of Fibrogenic Markers and Myocilin in Trabecular Meshwork Cells.

Authors:  Padmanabhan Paranji Pattabiraman; Ponugoti Vasantha Rao
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-08       Impact factor: 4.799

3.  Long-term stability of uveitis with faint anterior chamber flare treated with once-daily topical ophthalmic betamethasone.

Authors:  Masahide Kawamura; Masahiro Zako
Journal:  Inflammation       Date:  2014-04       Impact factor: 4.092

4.  A magnetic bead-based method for mouse trabecular meshwork cell isolation.

Authors:  Weiming Mao; Yang Liu; Robert J Wordinger; Abbot F Clark
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-05-01       Impact factor: 4.799

5.  Anti-inflammatory effect of Heliotropium indicum Linn on lipopolysaccharide-induced uveitis in New Zealand white rabbits.

Authors:  Samuel Kyei; George Asumeng Koffuor; Paul Ramkissoon; Elvis Ofori Ameyaw; Emmanuel Akomanin Asiamah
Journal:  Int J Ophthalmol       Date:  2016-04-18       Impact factor: 1.779

6.  Ultrastructural changes associated with dexamethasone-induced ocular hypertension in mice.

Authors:  Darryl R Overby; Jacques Bertrand; Ozan-Yüksel Tektas; Alexandra Boussommier-Calleja; Martin Schicht; C Ross Ethier; David F Woodward; W Daniel Stamer; Elke Lütjen-Drecoll
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-07-15       Impact factor: 4.799

7.  Outcomes of Ahmed glaucoma valve implantation for steroid-induced elevated intraocular pressure in patients with retinitis pigmentosa.

Authors:  Umit Eksioglu; Caglar Oktem; Gulten Sungur; Mehmet Yakin; Gulizar Demirok; Firdevs Ornek
Journal:  Int Ophthalmol       Date:  2017-07-21       Impact factor: 2.031

Review 8.  Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine.

Authors:  M Elizabeth Fini; Stephen G Schwartz; Xiaoyi Gao; Shinwu Jeong; Nitin Patel; Tatsuo Itakura; Marianne O Price; Francis W Price; Rohit Varma; W Daniel Stamer
Journal:  Prog Retin Eye Res       Date:  2016-09-22       Impact factor: 21.198

9.  RhoA GTPase-induced ocular hypertension in a rodent model is associated with increased fibrogenic activity in the trabecular meshwork.

Authors:  Padmanabhan P Pattabiraman; Tommy Rinkoski; Eric Poeschla; Alan Proia; Pratap Challa; Ponugoti V Rao
Journal:  Am J Pathol       Date:  2014-12-12       Impact factor: 4.307

10.  Development of a gene therapy virus with a glucocorticoid-inducible MMP1 for the treatment of steroid glaucoma.

Authors:  Maria-Grazia Spiga; Teresa Borrás
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-20       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.